These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

76 related articles for article (PubMed ID: 17458306)

  • 1. [Current status of new drug development for metabolic syndrome].
    Yokode M
    Nihon Rinsho; 2006 Dec; 64 Suppl 9():707-11. PubMed ID: 17458306
    [No Abstract]   [Full Text] [Related]  

  • 2. [Development of the treatment of metabolic syndrome by targeting modification of signaling molecules].
    Ueki K
    Nihon Rinsho; 2011 Jan; 69 Suppl 1():700-4. PubMed ID: 21766684
    [No Abstract]   [Full Text] [Related]  

  • 3. Inhibition of 11beta-HSD1 as a novel treatment for the metabolic syndrome: do glucocorticoids play a role?
    Thieringer R; Hermanowski-Vosatka A
    Expert Rev Cardiovasc Ther; 2005 Sep; 3(5):911-24. PubMed ID: 16181035
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FXR: a promising target for the metabolic syndrome?
    Cariou B; Staels B
    Trends Pharmacol Sci; 2007 May; 28(5):236-43. PubMed ID: 17412431
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Intracellular glucocorticoid reactivating enzyme, 11beta-HSD1 as a promising drug target against metabolic syndrome].
    Masuzaki H; Ishii T; Nakao K
    Nihon Rinsho; 2006 Dec; 64 Suppl 9():690-6. PubMed ID: 17458303
    [No Abstract]   [Full Text] [Related]  

  • 6. [Current status of the therapeutic effects of angiotensin converting enzyme inhibitors on metabolic syndrome].
    Zhao LY
    Zhonghua Yi Xue Za Zhi; 2006 Aug; 86(30):2091-2. PubMed ID: 17064608
    [No Abstract]   [Full Text] [Related]  

  • 7. Hidden disruptions in metabolic syndrome: drug-induced nutrient depletion as a pathway to accelerated pathophysiology of metabolic syndrome.
    LaValle JB
    Altern Ther Health Med; 2006; 12(2):26-31; quiz 32-3. PubMed ID: 16541994
    [No Abstract]   [Full Text] [Related]  

  • 8. Drug development research: diabetes favored over cardiovascular disease?
    Suckling K
    Curr Opin Investig Drugs; 2009 Mar; 10(3):217-9. PubMed ID: 19333877
    [No Abstract]   [Full Text] [Related]  

  • 9. Update on therapeutic strategies to increase adiponectin function and secretion in metabolic syndrome.
    Montecucco F; Mach F
    Diabetes Obes Metab; 2009 May; 11(5):445-54. PubMed ID: 19220391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of fibrate, ezetimibe, low- and high-dose statin therapy for the dyslipidemia of the metabolic syndrome in a mouse model.
    Paraskevas KI; Pantopoulou A; Vlachos IS; Agrogiannis G; Iliopoulos DG; Karatzas G; Tzivras D; Mikhailidis DP; Perrea DN
    Angiology; 2011 Feb; 62(2):144-54. PubMed ID: 21220373
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug therapy of the metabolic syndrome: minimizing the emerging crisis in polypharmacy.
    Grundy SM
    Nat Rev Drug Discov; 2006 Apr; 5(4):295-309. PubMed ID: 16582875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Metabolic syndrome, new onset diabetes, and new end points in cardiovascular trials.
    Haffner SM; Ruilope L; Dahlöf B; Abadie E; Kupfer S; Zannad F
    J Cardiovasc Pharmacol; 2006 Mar; 47(3):469-75. PubMed ID: 16633092
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of metabolic syndrome: statins.
    Xydakis AM; Ballantyne CM
    Endocrinol Metab Clin North Am; 2004 Sep; 33(3):509-23, vi. PubMed ID: 15262294
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiopoietin-like proteins: potential new targets for metabolic syndrome therapy.
    Oike Y; Akao M; Kubota Y; Suda T
    Trends Mol Med; 2005 Oct; 11(10):473-9. PubMed ID: 16154386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An update on lipidomics: progress and application in biomarker and drug development.
    Han X
    Curr Opin Mol Ther; 2007 Dec; 9(6):586-91. PubMed ID: 18041669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Welcome to new insights into 'Metabolic Syndrome'.
    Matyus P
    Future Med Chem; 2010 Dec; 2(12):1719-20. PubMed ID: 21428793
    [No Abstract]   [Full Text] [Related]  

  • 17. Recent advances in the discovery of 11beta-HSD1 inhibitors.
    Boyle CD
    Curr Opin Drug Discov Devel; 2008 Jul; 11(4):495-511. PubMed ID: 18600567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Fibrate and its perspective as a drug for metabolic syndrome].
    Tada N
    Nihon Rinsho; 2006 Dec; 64 Suppl 9():622-6. PubMed ID: 17458293
    [No Abstract]   [Full Text] [Related]  

  • 19. Carbenoxolone treatment attenuates symptoms of metabolic syndrome and atherogenesis in obese, hyperlipidemic mice.
    Nuotio-Antar AM; Hachey DL; Hasty AH
    Am J Physiol Endocrinol Metab; 2007 Dec; 293(6):E1517-28. PubMed ID: 17878220
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New approach in the treatment of T2DM and metabolic syndrome (focus on a novel insulin sensitizer).
    Tjokroprawiro A
    Acta Med Indones; 2006; 38(3):160-6. PubMed ID: 17119268
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.